The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models
N. Fitch, M. S. Freeman, R. G. Sturton, P. Harris, D. Lindell, R. Gundel (Berkeley, United States Of America; Stoke Poges, United Kingdom)
Source: Annual Congress 2001 - New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
N. Fitch, M. S. Freeman, R. G. Sturton, P. Harris, D. Lindell, R. Gundel (Berkeley, United States Of America; Stoke Poges, United Kingdom). The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models. Eur Respir J 2001; 16: Suppl. 31, 342
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
A selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004 Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
Effect of phosphodiesterase 4 (PDE-4) inhibitor – rolipram with or without co-administration of dexamethasone on experimental asthma - guinea pig model Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
Efficacy of the PDE4 inhibitor, BAY 19-8004, in a smoke-induced model of pulmonary inflammation in the guinea pig Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Ensifentrine, a novel dual phosphodiesterase (PDE) 3 and 4 inhibitor, provides effective bronchodilation when administered by dry powder inhaler in COPD Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019
The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Smoking has no effect on the pharmacokinetics of roflumilast, a new, orally active, selective PDE4 inhibitor Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
No interaction of roflumilast, a new, orally active, selective PDE4 inhibitor, with inhaled salbutamol Source: Eur Respir J 2001; 18: Suppl. 33, 156s Year: 2001
Combined inhalation of iloprost and the dual selective phosphodiesterase (PDE) inhibitor tolafentrine in a model of acute pulmonary hypertension Source: Eur Respir J 2001; 18: Suppl. 33, 198s Year: 2001
PDE isozymes and effects of selective PDE inhibitors on human lung fibroblasts (Fbs) Source: Eur Respir J 2005; 26: Suppl. 49, 551s Year: 2005